HMPC: overview of assessment work - priority list

Qualification of novel methodologies for medicine development (QoNM)

Qualification of novel methodologies for medicine development: High-level information on CHMP qualification advice

Qualification of novel methodologies for medicine development: High-level information on CHMP qualification advice

Risk management information day 2022, Online, European Medicines Agency, Amsterdam, the Netherlands, 9 December 2022

Appendix 1: Acceptable intakes established for N-nitrosamines

Human medicines European public assessment report (EPAR): Rhokiinsa, netarsudil, Date of authorisation: 19/11/2019, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Roclanda, latanoprost / netarsudil, Date of authorisation: 07/01/2021, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Duvyzat, givinostat, Date of authorisation: 06/06/2025, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Revision: 4, Status: Authorised